Search results for "ASTER"

showing 10 items of 2223 documents

5‐Alpha reductase inhibitors in androgenetic alopecia: Shifting paradigms, current concepts, comparative efficacy, and safety

2020

Androgenetic alopecia (AGA) is a multifactorial disease that carries a significant psychological burden with it. Dihydrotestosterone, the main pathogenic androgen in AGA, is produced by conversion of testosterone, which is catalyzed by the 5-alpha reductase (5-AR) isoenzyme family. Finasteride and dutasteride are inhibitors of these enzymes. Finasteride, which is a single receptor 5-alpha reductase inhibitor (5-ARI), acts by blocking dihydrotestosterone (DHT). Dutasteride, a dual receptor DHT blocker, has a higher potency than its predecessor, finasteride. This review corroborates the evidence of superiority of dutasteride over finasteride, and its comparable safety profile concerning ferti…

medicine.drug_classDermatologyReductasePharmacology030207 dermatology & venereal diseases03 medical and health sciences5 Alpha-Reductase Inhibitorchemistry.chemical_compound5-alpha Reductase Inhibitors0302 clinical medicinemedicineHumansTestosteronebusiness.industryFinasterideNeurotoxicityAlopeciaAndrogen AntagonistsGeneral MedicineDutasterideDutasteridemedicine.diseaseAndrogenchemistry030220 oncology & carcinogenesisDihydrotestosteroneFinasteridebusinessmedicine.drugDermatologic Therapy
researchProduct

Anti-inflammatory activity in mice of extracts from Mediterranean marine invertebrates.

1998

The effects of dichloromethane and methanol extracts from the marine invertebrates Leptogorgia ceratophyta, Holothuria tubulosa, Coscinasterias tenuispina and Phallusia fumigata on carrageenan-induced paw oedema in mice were investigated. The dichloromethane extract of Coscinasterias tenuispina and the methanol extract of Holothuria tubulosa administered p.o. at 50, 100 and 150 mg/kg, inhibited oedema in a dose-dependent manner 3 h after administration of carrageenan. Both extracts partially decreased elastase activity and PGE2 levels measured in homogenates from inflamed paws, without affecting the levels of this prostanoid present in stomach homogenates. As observed with the selective inh…

medicine.drug_classIndomethacinMarine BiologyPharmacologyBiologyCarrageenanGeneral Biochemistry Genetics and Molecular BiologyAnti-inflammatoryDinoprostonechemistry.chemical_compoundMicemedicineAnimalsEdemaGeneral Pharmacology Toxicology and Pharmaceuticschemistry.chemical_classificationPancreatic ElastaseElastaseHolothuria tubulosaAnti-Inflammatory Agents Non-SteroidalGeneral MedicineMarine invertebratesbiology.organism_classificationInvertebratesCarrageenanEnzymechemistryBiochemistryCoscinasterias tenuispinaFemaleCyclo-oxygenaseLife sciences
researchProduct

Anti-androgens for the treatment of hirsutism.

2002

Many alternatives exist for treating hirsutism. Based on an analysis of scientific literature and on the experiences of the author, the most common anti-androgen agents are discussed in this review. Androgen receptor blockers (cyproterone acetate, flutamide and spironolactone), 5 alpha-reductase inhibitors (finasteride) and androgen-suppressing agents (gonadotrophin-releasing hormone [GnRH] agonists, oestroprogestins, corticosteroids and insulin-sensitising agents) are evaluated and compared. The importance of diagnosis in choosing the most appropriate anti-androgen treatment is also discussed.

medicine.medical_specialtyCholestenone 5 alpha-ReductaseHirsutismAnti-Androgenurologic and male genital diseasesFlutamideGonadotropin-Releasing Hormonechemistry.chemical_compoundInternal medicineAndrogen Receptor AntagonistsMedicineHumansPharmacology (medical)Androgen Receptor AntagonistshirsutismPharmacologybusiness.industryCyproterone acetateAndrogen AntagonistsGeneral Medicinemedicine.diseaseAndrogen receptorEndocrinologyTreatment OutcomechemistrySpironolactoneFinasterideAndrogensFemalebusinessOxidoreductasesExpert opinion on investigational drugs
researchProduct

SGLT2 inhibitors in T2D and associated comorbidities - differentiating within the class

2019

Abstract Background For patients with type 2 diabetes (T2D), cardiovascular disease (CVD) is the single most common cause of mortality. In 2008 and 2012, the Federal Drug Administration (FDA) and the European Medicines Agency (EMA) respectively mandated cardiovascular outcomes trials (CVOTs) on all new anti-diabetic agents, as prospective trials statistically powered to rule out excess cardiovascular risk in patients with T2D. Unexpectedly, some of these CVOTs have demonstrated not only cardiovascular safety, but also cardioprotective effects, as was first shown for the SGLT2 inhibitor empagliflozin in EMPA-REG OUTCOME. Expert opinion To debate newly available CVOT data and to put them into…

medicine.medical_specialtyDiabetes mellitus type 2 ; drug therapy ; Cardiovascular diseases ; drug therapy ; Canagliflozin ; therapeutic use ; Benzhydryl compounds ; therapeutic use ; Glucosides ; therapeutic use ; Sodium-Glucose Transporter 2 Inhibitors ; therapeutic useEndocrinology Diabetes and MetabolismEmpagliflozin610 Medicine & health030209 endocrinology & metabolismContext (language use)ComorbidityType 2 diabetesDiseaseCanagliflozin ; Cardiovascular disease ; Dapagliflozin ; Empagliflozin ; SGLT2 inhibitor ; Type 2 diabetes.lcsh:Diseases of the endocrine glands. Clinical endocrinology03 medical and health scienceschemistry.chemical_compound0302 clinical medicineDiabetes mellitusCorrespondenceEmpagliflozinHumansMedicine030212 general & internal medicineCanagliflozinDapagliflozinIntensive care medicineSodium-Glucose Transporter 2 InhibitorsCanagliflozinlcsh:RC648-665business.industryIncidence616.379-008.64 [udc]Type 2 diabetesSGLT2 inhibitorGeneral MedicineDapagliflozinCardiovascular diseasePrognosismedicine.disease3. Good healthEastern europeanDiabetes Mellitus Type 2chemistryCardiovascular Diseasesbusinessmedicine.drug
researchProduct

Paradoxical attenuation of leukocyte rolling in response to ischemia- reperfusion and extracorporeal blood circulation in inflamed tissue.

2005

In contrast to acute preparations such as the exteriorized mesentery or the cremaster muscle, chronically instrumented chamber models allow one to study the microcirculation under “physiological” conditions, i.e., in the absence of trauma-induced leukocyte rolling along the venular endothelium. To underscore the importance of studying the naive microcirculation, we implanted titanium dorsal skinfold chambers in hamsters and used intravital fluorescence microscopy to study venular leukocyte rolling in response to ischemia-reperfusion injury or extracorporeal blood circulation. The experiments were performed in chambers that fulfilled all well-established criteria for a physiological microcir…

medicine.medical_specialtyExtracorporeal CirculationPhysiologyIschemiaLeukocyte RollingLeukotriene B4ExtracorporealMicrocirculationVenulesPhysiology (medical)Internal medicineCricetinaeMedicineAnimalsLeukocyte RollingMuscle SkeletalMesocricetusMyositisbusiness.industryExtracorporeal circulationAnatomymedicine.diseaseMicroscopy FluorescenceReperfusion InjuryCremaster muscleCirculatory systemCardiologyCardiology and Cardiovascular MedicinebusinessReperfusion injuryAmerican journal of physiology. Heart and circulatory physiology
researchProduct

Overview of health care provision for adult congenital heart disease (ACHD) in Central and South-eastern European countries: current status, provisio…

2020

Abstract Background Most of North and Western European countries recognized long ago the importance of specialized ACHD programmes and have today well-established Centre of excellence for management of ACHD patients. In contrast, even though Central and South-eastern (CESE) European region geographically comprise almost half of the European continent, little is known about ACHD status in vast majority of its countries. Purpose We aim to provide for the first time contemporary comprehensive overview of ACHD situation in CESE Europe. Methods We obtained data regarding current national ACHD status from 19 CESE European countries. Over the country national cardiac society, the ESC Working Group…

medicine.medical_specialtyGovernmentHeart diseasebusiness.industryWorkload030204 cardiovascular system & hematologymedicine.disease3. Good health03 medical and health sciences0302 clinical medicineCardiac Surgery proceduresEpidemiologyHealth caremedicineCardiology and Cardiovascular MedicineIntensive care medicinebusinessCardiac CathetersSouth easternEuropean Heart Journal
researchProduct

Non-Hemodynamic Effects of Organic Nitrates and the Distinctive Characteristics of Pentaerithrityl Tetranitrate

2009

Organic nitrates are among the oldest and yet most commonly employed drugs in the long-term therapy of coronary artery disease and congestive heart failure. While they have long been used in clinical practice, our understanding of their mechanism of action and side effects remains incomplete. For instance, recent findings provide evidence of previously unanticipated, non-hemodynamic properties that include potentially beneficial mechanisms (such as the induction of a protective phenotype that mimics ischemic preconditioning), but also toxic effects (such as endothelial and autonomic dysfunction, rebound angina, tolerance). To date, the most commonly employed organic nitrates are isosorbide …

medicine.medical_specialtyHeart DiseasesVasodilator AgentsIsosorbide DinitratePharmacologyDrug Administration ScheduleAnginaCoronary artery diseaseNitroglycerinmedicineIsosorbide mononitrateAnimalsHumansPentaerythritol TetranitratePharmacology (medical)NitroglycerinNitratesbusiness.industryDrug ToleranceGeneral Medicinemedicine.diseaseSurgeryEastern europeanOxidative StressHeart failureIschemic preconditioningIsosorbide dinitrateReactive Oxygen SpeciesCardiology and Cardiovascular Medicinebusinessmedicine.drugAmerican Journal of Cardiovascular Drugs
researchProduct

Blood pressure variability and cardiovascular risk in 9 eastern european countries: data from the BP-Care study

2015

Methods: Total 327 patients were enrolled from 2008 to 2011 in the Korean registry program. They met the criteria of PAH and we investigated the clinical data, the medication prescribed and survival status et al. Results: Their mean age was 40.8 15.8years with female /male patient ratio of 2.7:1. The patients in WHO I/II were 32.4% and WHO III/IV were 67.6%. The peak/mean pulmonary arterial pressure was 86.3/ 56.6 mmHg. Idiopathic PAH (22%), connective tissue disease (24%) and congenital heart disease (46%) were predominant. Small number of patients with familial PAH, portal hypertension, HIV infection, pulmonary capillary hemangiomatosis (PCH) existed. The patients described bosentan were …

medicine.medical_specialtyHeart diseasebusiness.industrySildenafilPulmonary capillary hemangiomatosismedicine.diseaseBosentanEastern europeanchemistry.chemical_compoundBlood pressurechemistryInternal medicineInternal MedicinemedicineCardiology and Cardiovascular MedicinebusinessSurvival ratemedicine.drugCohort studyJournal of the American Society of Hypertension
researchProduct

The Global Campaign (GC) to Reduce the Burden of Headache Worldwide. The International Team for Specialist Education (ITSE)

2005

The social perception of headache, everywhere at low levels in industrialised countries, becomes totally absent in developing ones. Headache disorders came into the World Health Organization’s strategic priorities after publication of the 2001 World Health Report. Among the leading causes of disability, migraine was ranked 19th for adults of both sexes together and 12th for females. The Global Campaign (GC) to Reduce the Burden of Headache Worldwide was planned by the major international headache organizations together with WHO in order to identify and remove those cultural, social and educational barriers recognised as responsible factors for the inadequate treatment of headache disorders …

medicine.medical_specialtyPain medicineeducationClinical SciencesGlobal Campaign Against HeadacheClinical NeurologyAlternative medicineMEDLINEWorld Health OrganizationGlobal Healthmasterin headache medicineWorld healthEducationMigrainesClinical ResearchMedicalacademic formation; global campaign against headache; headache specialist education; masterin headache medicineHealth careGeneticsGlobal healthHumansMedicineHeadache specialist educationDental/Oral and Craniofacial DiseaseGraduateNeurology & NeurosurgeryHeadachesbusiness.industrySocial perceptionPain ResearchHeadacheNeurosciencesMaster in Headache MedicineGeneral Medicinemedicine.diseaseHeadaches Physicians and PatientsAcademic formationQuality EducationAnesthesiology and Pain MedicineNeurologyMigraineEducation Medical GraduateFamily medicineNeurology (clinical)Chronic PainbusinessThe Journal of Headache and Pain
researchProduct

The dilemma for patients with chronic hepatitis C: treat now or warehouse?

2013

Dual therapy with peginterferon and ribavirin, the only treatent for chronic hepatitis C available In Italy and in many other ountries worldwide up to 2013, obtains satisfactory response ates in infections with hepatitis C virus (HCV) genotype 2, but far rom optimal for other genotypes [1,2]. Eradication requires 6–12 onths of therapy, with significant inconvenience for patients: dverse reactions force premature termination in about 20% of atients and reduced the quality of life for almost all who persist n treatment. In view of the important and prolonged side effects, nterferon-based treatment is perceived as a nightmare by many symptomatic,well-being, socially activepatients (the largema…

medicine.medical_specialtyPediatricsTime FactorsProlineHepatitis C virusAlpha interferonmedicine.disease_causeAntiviral AgentsTelaprevirPolyethylene Glycolschemistry.chemical_compoundLiver diseaseBoceprevirDrug DiscoveryRibavirinmedicineHumansProtease InhibitorsAdverse effectWatchful WaitingDrug CarriersHepatologybusiness.industryRibavirinGastroenterologyInterferon-alphaHepatitis C Chronicmedicine.diseaseSurgeryEastern europeanchemistryHCVDrug Therapy CombinationbusinessOligopeptidesmedicine.drugDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
researchProduct